PL375586A1 - Podstawione pochodne amidu kwasu antranilowego oraz sposoby wykorzystania - Google Patents
Podstawione pochodne amidu kwasu antranilowego oraz sposoby wykorzystaniaInfo
- Publication number
- PL375586A1 PL375586A1 PL03375586A PL37558603A PL375586A1 PL 375586 A1 PL375586 A1 PL 375586A1 PL 03375586 A PL03375586 A PL 03375586A PL 37558603 A PL37558603 A PL 37558603A PL 375586 A1 PL375586 A1 PL 375586A1
- Authority
- PL
- Poland
- Prior art keywords
- methods
- amide derivatives
- substituted anthranilic
- anthranilic amide
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39514402P | 2002-07-09 | 2002-07-09 | |
US10/615,809 US7307088B2 (en) | 2002-07-09 | 2003-07-08 | Substituted anthranilic amide derivatives and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
PL375586A1 true PL375586A1 (pl) | 2005-11-28 |
Family
ID=30118477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL03375586A PL375586A1 (pl) | 2002-07-09 | 2003-07-09 | Podstawione pochodne amidu kwasu antranilowego oraz sposoby wykorzystania |
Country Status (8)
Country | Link |
---|---|
US (1) | US7307088B2 (pl) |
EP (1) | EP1519921A2 (pl) |
JP (1) | JP2006502112A (pl) |
AU (1) | AU2003256481B2 (pl) |
CA (1) | CA2489166A1 (pl) |
MX (1) | MXPA05000120A (pl) |
PL (1) | PL375586A1 (pl) |
WO (1) | WO2004005279A2 (pl) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
NZ544797A (en) | 2003-07-18 | 2011-04-29 | Amgen Fremont Inc | Specific antibodies that bind HGF and neutralise binding of HGF to met |
US20050130986A1 (en) * | 2003-11-21 | 2005-06-16 | Eklund Kari K. | Treatment of spondylarthropathies |
US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) * | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
WO2006060318A2 (en) | 2004-11-30 | 2006-06-08 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
JP4834441B2 (ja) * | 2005-03-31 | 2011-12-14 | 参天製薬株式会社 | ピリミジニルアルキルチオ基を有する新規環式化合物 |
ES2548729T3 (es) * | 2005-03-31 | 2015-10-20 | Santen Pharmaceutical Co., Ltd. | Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio |
US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
CA2629964A1 (en) | 2005-11-30 | 2007-06-07 | Astellas Pharma Inc. | 2-aminobenzamide derivative |
US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
EP1987023B1 (en) | 2006-02-10 | 2010-11-24 | Amgen, Inc | Hydrate forms of amg706 |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
ES2449482T3 (es) | 2007-01-09 | 2014-03-19 | Amgen Inc. | Derivados de bis-aril-amida útiles para el tratamiento de cáncer |
US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
US8586571B2 (en) | 2007-10-18 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2010019473A1 (en) | 2008-08-14 | 2010-02-18 | Amgen Inc. | Aurora kinase modulators and methods of use |
EP2376448A2 (en) * | 2008-12-19 | 2011-10-19 | Amgen, Inc | Improved method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole |
CN105924386A (zh) | 2009-03-25 | 2016-09-07 | Abbvie 公司 | 抗病毒化合物和其用途 |
CN102459209A (zh) * | 2009-04-16 | 2012-05-16 | 武田药品工业株式会社 | 用于预防或治疗糖尿病(等)的n-酰基-n’-苯基哌嗪的衍生物 |
WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
PT2688887E (pt) | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
AU2015326506B2 (en) | 2014-10-03 | 2021-02-25 | Divya MAHESHWARI | Novel anthranilic acid derivatives |
AU2016205311B2 (en) | 2015-01-08 | 2022-02-17 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
EP3795568A1 (en) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
US10766860B2 (en) | 2015-03-06 | 2020-09-08 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
KR102615565B1 (ko) | 2016-09-07 | 2023-12-18 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
WO2018048943A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
JOP20190154B1 (ar) | 2016-12-22 | 2022-09-15 | Amgen Inc | بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم |
AR110963A1 (es) * | 2017-02-07 | 2019-05-22 | Dae Woong Pharma | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
US11446279B2 (en) | 2017-06-29 | 2022-09-20 | The Regents Of The University Of California | Aromatic 2-nitrosulfonyl fluoride antibiotics and methods of use thereof |
CN109422655B (zh) * | 2017-08-24 | 2021-10-29 | 中国石油化工股份有限公司 | 一种苯酚直接氨化制苯胺的方法 |
ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MA52496A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MX2020011907A (es) | 2018-05-10 | 2021-01-29 | Amgen Inc | Inhibidores de kras g12c para el tratamiento de cancer. |
CA3098885A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
EP3802537A1 (en) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CA3117222A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
CA3123044A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
JP2022513967A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
MX2021007104A (es) | 2018-12-20 | 2021-08-11 | Amgen Inc | Inhibidores de kif18a. |
MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
CN113767100A (zh) | 2019-03-01 | 2021-12-07 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CN114144414A (zh) | 2019-05-21 | 2022-03-04 | 美国安进公司 | 固态形式 |
JP2022542392A (ja) | 2019-08-02 | 2022-10-03 | アムジエン・インコーポレーテツド | Kif18a阻害剤としてのピリジン誘導体 |
CN114302880A (zh) | 2019-08-02 | 2022-04-08 | 美国安进公司 | Kif18a抑制剂 |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
CA3147272A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
JP2022553859A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
TW202132315A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras 抑制劑 |
BR112022008565A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras |
CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
MX2022005708A (es) | 2019-11-14 | 2022-06-08 | Amgen Inc | Sintesis mejorada del compuesto inhibidor de g12c de kras. |
MX2022005726A (es) | 2019-11-14 | 2022-06-09 | Amgen Inc | Sintesis mejorada del compuesto inhibidor de g12c de kras. |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
JP2023509701A (ja) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ,インコーポレイテッド | Shp2阻害剤投薬およびがんを処置する方法 |
IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
AR124449A1 (es) | 2020-12-22 | 2023-03-29 | Qilu Regor Therapeutics Inc | Inhibidores de sos1 y usos de los mismos |
CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
EP4334321A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH438343A (de) | 1962-11-08 | 1967-06-30 | Thomae Gmbh Dr K | Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen |
US3226394A (en) | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
US3822277A (en) | 1967-11-13 | 1974-07-02 | C Dufour | Certain pyridyl cyclopropylamides |
US3452019A (en) | 1967-11-16 | 1969-06-24 | Wallace & Tiernan Inc | 1-phenylalkyl-tetrahydro-halo-sulfamyl-quinazolinone |
US3557111A (en) | 1968-03-29 | 1971-01-19 | Bola Vithal Shetty | N and n,n-alkyl,acyl and arylsulfamyl-tetrahydroquinazolinones |
US3567746A (en) | 1968-07-10 | 1971-03-02 | Pennwalt Corp | N-aryl benzamides |
BE794226A (fr) | 1972-01-21 | 1973-07-18 | Synthelabo | Derives de la quinoleine, leur preparation et les medicaments qui en contiennent |
GB1474296A (en) | 1975-01-23 | 1977-05-18 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
GB1573186A (en) | 1977-09-14 | 1980-08-20 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
DE2934543A1 (de) | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
JPH0233030B2 (ja) | 1982-01-18 | 1990-07-25 | Mitsui Toatsu Chemicals | Surufuamoiruansokukosanjudotaioyobisoreojukoseibuntoshitefukumuchiryoyososeibutsu |
FR2540870A1 (fr) | 1983-02-15 | 1984-08-17 | Provesan Sa | Nouveaux derives de betaines n-iminopyridinium, leur preparation et leur application en tant que medicaments |
SU1156362A1 (ru) | 1983-02-17 | 1991-07-30 | Пермский государственный фармацевтический институт | Ариламиды П-(2 @ ,4 @ )- или (3 @ ,4 @ )-диметоксибензилантраниловых кислот как промежуточные вещества дл синтеза биологически активных перхлоратов 1-[(2 @ ,4 @ ) или (3 @ ,4 @ )-диметоксибензил]-2-метил-3-арил-4-(3Н)-хиназолинони |
DE3305755A1 (de) | 1983-02-19 | 1984-08-23 | Gödecke AG, 1000 Berlin | N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems |
EP0393529B1 (en) | 1989-04-20 | 1993-06-30 | Boehringer Ingelheim Pharmaceuticals Inc. | 5,11-dihydro-6H-dipyrido [3,2-b:2',3'-e][1,4]diazepin-6-ones and their use in the prevention or treatment of AIDS |
ATE103918T1 (de) | 1989-06-28 | 1994-04-15 | Boehringer Ingelheim Pharma | 5,11-dihydro-6h-dipyrido(3,2-b:2',3'e>(1,4>diazepin-6-one und -thione und ihre verwendung bei der aids-vorbeugung oder behandlung. |
CA2030056C (en) | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
US5571912A (en) | 1990-10-19 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines |
EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
US5559135A (en) | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
US5532358A (en) | 1994-10-12 | 1996-07-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5663357A (en) | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
US6008234A (en) | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
ID22781A (id) | 1997-04-04 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan nikotinamida |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
CA2294126A1 (en) | 1997-06-26 | 1999-01-07 | Douglas Wade Beight | Antithrombotic agents |
JP2002512633A (ja) | 1997-06-26 | 2002-04-23 | イーライ・リリー・アンド・カンパニー | 抗血栓剤 |
AU8269398A (en) | 1997-06-26 | 1999-01-19 | Eli Lilly And Company | Antithrombotic agents |
US6372759B1 (en) | 1997-06-26 | 2002-04-16 | Eli Lilly And Company | Antithrombotic agents |
US6140351A (en) | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
JP3811006B2 (ja) | 1997-12-19 | 2006-08-16 | シエーリング アクチエンゲゼルシャフト | 抗凝血物質類としてのオルト−アントラニルアミド誘導体類 |
US6271237B1 (en) | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
JP2002516909A (ja) | 1998-06-05 | 2002-06-11 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換1−(4−アミノフェニル)ピラゾール及び抗炎症剤としてのそれらの使用 |
DE69928260T2 (de) | 1998-07-08 | 2006-07-20 | Sanofi-Aventis Deutschland Gmbh | Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen |
US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
US6610704B1 (en) | 1998-12-23 | 2003-08-26 | Eli Lilly And Company | Antithrombotic amides |
CA2358095A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Heteroroaromatic amides as inhibitor of factor xa |
ES2226485T3 (es) | 1998-12-23 | 2005-03-16 | Eli Lilly And Company | Amidas aromaticas. |
JP2000256358A (ja) | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
DE19941540C2 (de) | 1999-09-01 | 2002-08-29 | Aventis Pharma Gmbh | Sulfonylcarboxamide zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidämie |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
AUPQ365299A0 (en) | 1999-10-25 | 1999-11-18 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives |
GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
EP1257536A1 (en) | 2000-01-27 | 2002-11-20 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP1259485B1 (en) | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
DE10023485A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
US6934248B1 (en) | 2000-07-20 | 2005-08-23 | Nortel Networks Limited | Apparatus and method for optical communication protection |
DE10060809A1 (de) | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
EP1394154A4 (en) | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID |
US7312235B2 (en) | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
CN1518546A (zh) * | 2001-05-08 | 2004-08-04 | ���ֹɷݹ�˾ | 作为vegrf-2和vegfr-3抑制剂的选择性邻氨基苯甲酰胺吡啶酰胺 |
WO2002090349A1 (de) * | 2001-05-08 | 2002-11-14 | Schering Aktiengesellschaft | N-oxidanthranylamid-derivate und deren verwendung als arzneimittel |
DE50206476D1 (de) * | 2001-05-08 | 2006-05-24 | Schering Ag | Cyanoanthranylamid-derivate und deren verwendung als arzneimittel |
DE10125295A1 (de) | 2001-05-15 | 2002-11-21 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) |
GB0126901D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
GB0126902D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
PL372756A1 (pl) | 2002-02-11 | 2005-08-08 | Pfizer Inc. | Pochodne nikotynoamidu jako inhibitory PDE 4 |
GB0203193D0 (en) | 2002-02-11 | 2002-03-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
US7517894B2 (en) | 2002-07-31 | 2009-04-14 | Bayer Schering Pharma Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
-
2003
- 2003-07-08 US US10/615,809 patent/US7307088B2/en active Active
- 2003-07-09 PL PL03375586A patent/PL375586A1/pl unknown
- 2003-07-09 MX MXPA05000120A patent/MXPA05000120A/es not_active Application Discontinuation
- 2003-07-09 WO PCT/US2003/021601 patent/WO2004005279A2/en active IP Right Grant
- 2003-07-09 EP EP03763451A patent/EP1519921A2/en not_active Withdrawn
- 2003-07-09 AU AU2003256481A patent/AU2003256481B2/en not_active Ceased
- 2003-07-09 CA CA002489166A patent/CA2489166A1/en not_active Abandoned
- 2003-07-09 JP JP2004520114A patent/JP2006502112A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2003256481A1 (en) | 2004-01-23 |
AU2003256481B2 (en) | 2007-08-09 |
CA2489166A1 (en) | 2004-01-15 |
US7307088B2 (en) | 2007-12-11 |
US20040087568A1 (en) | 2004-05-06 |
MXPA05000120A (es) | 2005-04-08 |
EP1519921A2 (en) | 2005-04-06 |
WO2004005279A2 (en) | 2004-01-15 |
JP2006502112A (ja) | 2006-01-19 |
WO2004005279A3 (en) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL375586A1 (pl) | Podstawione pochodne amidu kwasu antranilowego oraz sposoby wykorzystania | |
PL376566A1 (pl) | Pochodne podstawionych 2-alkiloamino-nikotynamidów oraz sposoby wykorzystania | |
PL377861A1 (pl) | Podstawione pochodne aminowe oraz sposoby wykorzystania | |
EP1465615A4 (en) | TRICYCLIC BISENONE DERIVATIVES AND METHODS OF USE | |
IL156737A0 (en) | Substituted amine derivatives and methods of use | |
AU2003303128A8 (en) | Inhibitors and methods of use thereof | |
PL376532A1 (pl) | Pochodne podstawionych benzyloamin oraz sposoby wykorzystania | |
AU2003217870A8 (en) | Pini-modulating compounds and methods of use thereof | |
HK1079789A1 (zh) | 血管靜態毒性試劑及其使用方法 | |
PL378331A1 (pl) | Tetracykliczne pochodne benzamidowe i sposoby ich stosowania | |
AU2003213673A8 (en) | Pin1-modulating compounds and methods of use thereof | |
EP1507756A4 (en) | CCR9 INHIBITORS AND USE THEREOF | |
EP1603568A4 (en) | ISOCHINOLINE DERIVATIVES AND METHOD OF USE THEREOF | |
ZA200500680B (en) | Quinoline derivatives and their use as mycrobacterial inhibitors | |
PL376575A1 (pl) | Podstawione związki heterocykliczne oraz sposoby wykorzystania | |
EP1497270A4 (en) | AMID COMPOUNDS AND METHOD FOR THEIR USE | |
IL173936A0 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
IL157659A0 (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
HK1068874A1 (en) | Heterocyclic compounds and methods of use | |
EP1549756A4 (en) | RECOMBINANT MUTANTS OF RHABDOVIRUS AND METHODS OF USE | |
PL377413A1 (pl) | Pochodne piryd-2-onu i sposoby ich zastosowania | |
EP1448218A4 (en) | BETA SECRETASE INHIBITORS AND METHODS OF USE | |
EP1476150A4 (en) | CARBOXY FULLERES AND USE METHOD THEREFOR | |
EP1625111A4 (en) | THYRONAMINE DERIVATIVES AND ANALOGUES AND METHODS OF USE THEREOF | |
EP1633749A4 (en) | DEAZAFLAVIN COMPOUNDS AND METHODS OF USE |